Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Expanding horizons: new roles for non-canonical RNA-binding proteins in cancer.

Moore S, Järvelin AI, Davis I, Bond GL, Castello A.

Curr Opin Genet Dev. 2018 Feb;48:112-120. doi: 10.1016/j.gde.2017.11.006. Epub 2017 Dec 5. Review.

2.

Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice.

Leroy B, Ballinger ML, Baran-Marszak F, Bond GL, Braithwaite A, Concin N, Donehower LA, El-Deiry WS, Fenaux P, Gaidano G, Langerød A, Hellstrom-Lindberg E, Iggo R, Lehmann-Che J, Mai PL, Malkin D, Moll UM, Myers JN, Nichols KE, Pospisilova S, Ashton-Prolla P, Rossi D, Savage SA, Strong LC, Tonin PN, Zeillinger R, Zenz T, Fraumeni JF Jr, Taschner PE, Hainaut P, Soussi T.

Cancer Res. 2017 Mar 15;77(6):1250-1260. doi: 10.1158/0008-5472.CAN-16-2179. Review.

3.

MEF2 transcription factors are key regulators of sprouting angiogenesis.

Sacilotto N, Chouliaras KM, Nikitenko LL, Lu YW, Fritzsche M, Wallace MD, Nornes S, García-Moreno F, Payne S, Bridges E, Liu K, Biggs D, Ratnayaka I, Herbert SP, Molnár Z, Harris AL, Davies B, Bond GL, Bou-Gharios G, Schwarz JJ, De Val S.

Genes Dev. 2016 Oct 15;30(20):2297-2309.

4.

CD44 SNPrs187115: A Novel Biomarker Signature that Predicts Survival in Resectable Pancreatic Ductal Adenocarcinoma.

Stracquadanio G, Vrugt B, Flury R, Schraml P, Würl P, Müller TH, Knippschild U, Henne-Bruns D, Breitenstein S, Clavien PA, Graf R, Bond GL, Grochola LF.

Clin Cancer Res. 2016 Dec 15;22(24):6069-6077. Epub 2016 Jun 9.

5.

A Polymorphic Antioxidant Response Element Links NRF2/sMAF Binding to Enhanced MAPT Expression and Reduced Risk of Parkinsonian Disorders.

Wang X, Campbell MR, Lacher SE, Cho HY, Wan M, Crowl CL, Chorley BN, Bond GL, Kleeberger SR, Slattery M, Bell DA.

Cell Rep. 2016 Apr 26;15(4):830-842. doi: 10.1016/j.celrep.2016.03.068. Epub 2016 Apr 14.

6.

Hypoxia Suppressed Copper Toxicity during Early Development in Zebrafish Embryos in a Process Mediated by the Activation of the HIF Signaling Pathway.

Fitzgerald JA, Jameson HM, Fowler VH, Bond GL, Bickley LK, Webster TM, Bury NR, Wilson RJ, Santos EM.

Environ Sci Technol. 2016 Apr 19;50(8):4502-12. doi: 10.1021/acs.est.6b01472. Epub 2016 Apr 11.

7.

The importance of p53 pathway genetics in inherited and somatic cancer genomes.

Stracquadanio G, Wang X, Wallace MD, Grawenda AM, Zhang P, Hewitt J, Zeron-Medina J, Castro-Giner F, Tomlinson IP, Goding CR, Cygan KJ, Fairbrother WG, Thomas LF, Sætrom P, Gemignani F, Landi S, Schuster-Böckler B, Bell DA, Bond GL.

Nat Rev Cancer. 2016 Apr;16(4):251-65. doi: 10.1038/nrc.2016.15. Review.

PMID:
27009395
8.

Homozygous G/G variant of SNP309 in the human MDM2 gene is associated with earlier tumor onset in Caucasian female renal cell carcinoma patients.

Stoehr CG, Stoehr R, Wenners A, Hartmann A, Bertz S, Spath V, Walter B, Junker K, Moch H, Hinze R, Denzinger S, Bond EE, Bond GL, Bluemke K, Weigelt K, Lieb V, Nolte E, Fornara P, Wullich B, Taubert H, Wach S.

Oncogenesis. 2016 Feb 29;5:e205. doi: 10.1038/oncsis.2016.15.

9.

Interaction between p53 mutation and a somatic HDMX biomarker better defines metastatic potential in breast cancer.

Grawenda AM, Møller EK, Lam S, Repapi E, Teunisse AF, Alnæs GI, Børresen-Dale AL, Kristensen VN, Goding CR, Jochemsen AG, Edvardsen H, Bond GL.

Cancer Res. 2015 Feb 15;75(4):698-708. doi: 10.1158/0008-5472.CAN-14-2637. Epub 2015 Feb 3.

10.

Radiation-induced apoptosis varies among individuals and is modified by sex and age.

Applebaum MA, Skol AD, Bond EE, Overholtzer M, Bond GL, Onel K.

Int J Radiat Biol. 2014 Oct;90(10):903-8. doi: 10.3109/09553002.2014.925603. Epub 2014 Jun 25.

11.

SNPing away at human skin color.

Wallace MD, Box NF, Bond GL.

Pigment Cell Melanoma Res. 2014 May;27(3):322-3. doi: 10.1111/pcmr.12229. Epub 2014 Mar 3. No abstract available.

PMID:
24517848
12.

A polymorphic p53 response element in KIT ligand influences cancer risk and has undergone natural selection.

Zeron-Medina J, Wang X, Repapi E, Campbell MR, Su D, Castro-Giner F, Davies B, Peterse EF, Sacilotto N, Walker GJ, Terzian T, Tomlinson IP, Box NF, Meinshausen N, De Val S, Bell DA, Bond GL.

Cell. 2013 Oct 10;155(2):410-22. doi: 10.1016/j.cell.2013.09.017.

13.

Hereditary and environmental epidemiology of sarcomas.

Thomas DM, Savage SA, Bond GL.

Clin Sarcoma Res. 2012 Oct 4;2(1):13. doi: 10.1186/2045-3329-2-13. No abstract available.

14.

Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer.

Lenos K, Grawenda AM, Lodder K, Kuijjer ML, Teunisse AF, Repapi E, Grochola LF, Bartel F, Hogendoorn PC, Wuerl P, Taubert H, Cleton-Jansen AM, Bond GL, Jochemsen AG.

Cancer Res. 2012 Aug 15;72(16):4074-84. Epub 2012 Jun 14.

15.

A RASSF1A polymorphism restricts p53/p73 activation and associates with poor survival and accelerated age of onset of soft tissue sarcoma.

Yee KS, Grochola L, Hamilton G, Grawenda A, Bond EE, Taubert H, Wurl P, Bond GL, O'Neill E.

Cancer Res. 2012 May 1;72(9):2206-17. doi: 10.1158/0008-5472.CAN-11-2906. Epub 2012 Mar 2.

16.

A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development.

Post SM, Quintás-Cardama A, Pant V, Iwakuma T, Hamir A, Jackson JG, Maccio DR, Bond GL, Johnson DG, Levine AJ, Lozano G.

Cancer Cell. 2010 Sep 14;18(3):220-30. doi: 10.1016/j.ccr.2010.07.010.

17.

A genetic variant in a PP2A regulatory subunit encoded by the PPP2R2B gene associates with altered breast cancer risk and recurrence.

Vazquez A, Kulkarni D, Grochola LF, Bond GL, Barnard N, Toppmeyer D, Levine AJ, Hirshfield KM.

Int J Cancer. 2011 May 15;128(10):2335-43. doi: 10.1002/ijc.25582.

18.

Single-nucleotide polymorphisms in the p53 signaling pathway.

Grochola LF, Zeron-Medina J, Mériaux S, Bond GL.

Cold Spring Harb Perspect Biol. 2010 May;2(5):a001032. doi: 10.1101/cshperspect.a001032. Epub 2009 Dec 9. Review.

19.

Chemosensitivity profiles identify polymorphisms in the p53 network genes 14-3-3tau and CD44 that affect sarcoma incidence and survival.

Vazquez A, Grochola LF, Bond EE, Levine AJ, Taubert H, Müller TH, Würl P, Bond GL.

Cancer Res. 2010 Jan 1;70(1):172-80. doi: 10.1158/0008-5472.CAN-09-2218. Epub 2009 Dec 8.

20.

Recent natural selection identifies a genetic variant in a regulatory subunit of protein phosphatase 2A that associates with altered cancer risk and survival.

Grochola LF, Vazquez A, Bond EE, Würl P, Taubert H, Müller TH, Levine AJ, Bond GL.

Clin Cancer Res. 2009 Oct 1;15(19):6301-8. doi: 10.1158/1078-0432.CCR-09-0797. Epub 2009 Sep 22.

21.

MDM2 SNP309 associates with accelerated pancreatic adenocarcinoma formation.

Grochola LF, Müller TH, Bond GL, Taubert H, Udelnow A, Würl P.

Pancreas. 2010 Jan;39(1):76-80. doi: 10.1097/MPA.0b013e3181b9f105.

PMID:
19752772
22.

Altered tumor formation and evolutionary selection of genetic variants in the human MDM4 oncogene.

Atwal GS, Kirchhoff T, Bond EE, Montagna M, Menin C, Bertorelle R, Scaini MC, Bartel F, Böhnke A, Pempe C, Gradhand E, Hauptmann S, Offit K, Levine AJ, Bond GL.

Proc Natl Acad Sci U S A. 2009 Jun 23;106(25):10236-41. doi: 10.1073/pnas.0901298106. Epub 2009 Jun 4. Erratum in: Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):12208. Monagna, Marco [corrected to Montagna, Marco].

23.

The genetics of the p53 pathway, apoptosis and cancer therapy.

Vazquez A, Bond EE, Levine AJ, Bond GL.

Nat Rev Drug Discov. 2008 Dec;7(12):979-87. doi: 10.1038/nrd2656. Review.

PMID:
19043449
24.

An information-theoretic analysis of genetics, gender and age in cancer patients.

Atwal GS, Rabadán R, Lozano G, Strong LC, Ruijs MW, Schmidt MK, van't Veer LJ, Nevanlinna H, Tommiska J, Aittomäki K, Bougeard G, Frebourg T, Levine AJ, Bond GL.

PLoS One. 2008 Apr 9;3(4):e1951. doi: 10.1371/journal.pone.0001951.

25.

Haplotype structure and selection of the MDM2 oncogene in humans.

Atwal GS, Bond GL, Metsuyanim S, Papa M, Friedman E, Distelman-Menachem T, Ben Asher E, Lancet D, Ross DA, Sninsky J, White TJ, Levine AJ, Yarden R.

Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4524-9. Epub 2007 Mar 5.

27.

MDM2 SNP309 accelerates colorectal tumour formation in women.

Bond GL, Menin C, Bertorelle R, Alhopuro P, Aaltonen LA, Levine AJ.

J Med Genet. 2006 Dec;43(12):950-2. Epub 2006 Jul 6.

28.

MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner.

Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, Robins H, Bartel F, Taubert H, Wuerl P, Hait W, Toppmeyer D, Offit K, Levine AJ.

Cancer Res. 2006 May 15;66(10):5104-10.

29.
30.

A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells.

Arva NC, Gopen TR, Talbott KE, Campbell LE, Chicas A, White DE, Bond GL, Levine AJ, Bargonetti J.

J Biol Chem. 2005 Jul 22;280(29):26776-87. Epub 2005 May 20.

31.

MDM2 is a central node in the p53 pathway: 12 years and counting.

Bond GL, Hu W, Levine AJ.

Curr Cancer Drug Targets. 2005 Feb;5(1):3-8. Review.

PMID:
15720184
32.

A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans.

Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, Levine AJ.

Cell. 2004 Nov 24;119(5):591-602.

33.

Identification and functional characterization of neo-poly(A) polymerase, an RNA processing enzyme overexpressed in human tumors.

Topalian SL, Kaneko S, Gonzales MI, Bond GL, Ward Y, Manley JL.

Mol Cell Biol. 2001 Aug;21(16):5614-23.

34.

Poly(A) polymerase phosphorylation is dependent on novel interactions with cyclins.

Bond GL, Prives C, Manley JL.

Mol Cell Biol. 2000 Jul;20(14):5310-20.

35.

Reading ease of commonly used tests.

JOHNSON RH, BOND GL.

J Appl Psychol. 1950 Oct;34(5):319-24. No abstract available.

PMID:
14784454

Supplemental Content

Support Center